• |
APX3330: End-of-Phase 2 (EOP2) meeting
scheduled with FDA to confirm Phase 3 regulatory path for oral APX3330 in DR (Q4 2023)
|
• |
Nyxol: PDUFA date for Nyxol in RM (September 28, 2023). FDA approval in RM would trigger a $10 million milestone payment to Ocuphire
|
• |
Nyxol: Topline results from VEGA-2 Phase 3
pivotal trial of Nyxol in Presbyopia (Q4 2023)
|
• |
A late-breaking poster and ePoster theater presentation featured results from ZETA-1 Phase 2 trial of APX3330 in DR at the 83rd Scientific Sessions of the American
Diabetes Association (ADA) in June 2023.
|
• |
Previously announced results from ZETA-1 Phase 2 trial of APX3330 in DR were presented to the medical community at the ASCRS Annual Meeting in May 2023.
|
• |
Results from LYNX-1 Phase 3 trial of Nyxol in DLD were presented for the first time to the medical community at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in
April 2023, and at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in May 2023.
|
Corporate
|
Investor Relations
|
Rick Rodgers
Interim President & CEO
|
Corey Davis, Ph.D.
LifeSci Advisors
|
As of
|
||||||||
June 30,
|
December 31,
|
|||||||
2023
(unaudited)
|
2022
|
|||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
39,977
|
$
|
42,634
|
||||
Accounts receivable
|
135
|
1,298
|
||||||
Contract assets and unbilled receivables
|
2,595
|
3,552
|
||||||
Prepaids and other current assets
|
732
|
1,453
|
||||||
Short-term investments
|
22
|
49
|
||||||
Total current assets
|
43,461
|
48,986
|
||||||
Property and equipment, net
|
4
|
6
|
||||||
Total assets
|
$
|
43,465
|
$
|
48,992
|
||||
|
||||||||
Liabilities and stockholders’ equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
2,323
|
$
|
1,069
|
||||
Accrued expenses
|
3,438
|
1,684
|
||||||
Total current liabilities
|
5,761
|
2,753
|
||||||
Total liabilities
|
5,761
|
2,753
|
||||||
|
||||||||
Commitments and contingencies
|
||||||||
|
||||||||
Stockholders’ equity
|
||||||||
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; no shares
issued and outstanding at June 30, 2023 and December 31, 2022.
|
—
|
—
|
||||||
Common stock, par value $0.0001; 75,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 20,985,784 and
20,861,315 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.
|
2
|
2
|
||||||
Additional paid-in capital
|
119,934
|
117,717
|
||||||
Accumulated deficit
|
(82,232
|
)
|
(71,480
|
)
|
||||
Total stockholders’ equity
|
37,704
|
46,239
|
||||||
Total liabilities and stockholders’ equity
|
$
|
43,465
|
$
|
48,992
|
For the Three Months Ended
|
For the Six Months Ended
|
|||||||||||||||
June 30,
|
June 30,
|
|||||||||||||||
2023
|
2022
|
2023
|
2022
|
|||||||||||||
License and collaborations revenue
|
$
|
3,674
|
$
|
—
|
$
|
5,423
|
$
|
—
|
||||||||
Operating expenses:
|
||||||||||||||||
General and administrative
|
4,340
|
1,776
|
6,625
|
3,512
|
||||||||||||
Research and development
|
4,723
|
3,162
|
10,318
|
7,934
|
||||||||||||
Total operating expenses
|
9,063
|
4,938
|
16,943
|
11,446
|
||||||||||||
Loss from operations
|
(5,389
|
)
|
(4,938
|
)
|
(11,520
|
)
|
(11,446
|
)
|
||||||||
Interest expense
|
—
|
(4
|
)
|
—
|
(9
|
)
|
||||||||||
Other income (expense), net
|
428
|
15
|
768
|
(67
|
)
|
|||||||||||
Loss before income taxes
|
(4,961
|
)
|
(4,927
|
)
|
(10,752
|
)
|
(11,522
|
)
|
||||||||
Benefit (provision) for income taxes
|
—
|
—
|
—
|
—
|
||||||||||||
Net loss
|
(4,961
|
)
|
(4,927
|
)
|
(10,752
|
)
|
(11,522
|
)
|
||||||||
Other comprehensive loss, net of tax
|
—
|
—
|
—
|
—
|
||||||||||||
Comprehensive loss
|
$
|
(4,961
|
)
|
$
|
(4,927
|
)
|
$
|
(10,752
|
)
|
$
|
(11,522
|
)
|
||||
Net loss per share:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.24
|
)
|
$
|
(0.25
|
)
|
$
|
(0.51
|
)
|
$
|
(0.60
|
)
|
||||
Number of shares used in per share calculations:
|
||||||||||||||||
Basic and diluted
|
20,959,807
|
19,502,563
|
20,949,763
|
19,197,213
|